VYNE Therapeutics Stock Set to Reverse Split on Monday, July 27th (NASDAQ:VYNE)

VYNE Therapeutics Inc. (NASDAQ:VYNE) shares are set to reverse split on the morning of Monday, July 27th. The 1-50 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Sunday, July 26th.

VYNE Therapeutics Trading Up 0.5%

VYNE stock opened at $0.90 on Thursday. The stock has a 50-day moving average price of $0.68 and a two-hundred day moving average price of $0.63. VYNE Therapeutics has a 12-month low of $0.28 and a 12-month high of $1.59. The company has a market cap of $29.96 million, a PE ratio of -2.36 and a beta of 2.00.

VYNE Therapeutics (NASDAQ:VYNE) last announced its quarterly earnings results on Friday, May 15th. The company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.10. The company had revenue of $0.09 million during the quarter, compared to analyst estimates of $0.20 million. VYNE Therapeutics had a negative return on equity of 70.42% and a negative net margin of 4,726.21%. Equities analysts forecast that VYNE Therapeutics will post -1.1 EPS for the current fiscal year.

VYNE Therapeutics Dividend Announcement

The company also recently announced a special dividend, which will be paid on Thursday, July 23rd. Stockholders of record on Wednesday, July 22nd will be issued a dividend of $0.38 per share.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of VYNE Therapeutics in a report on Monday, May 4th. Three investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Reduce”.

Institutional Trading of VYNE Therapeutics

Several large investors have recently added to or reduced their stakes in the stock. Anson Funds Management LP purchased a new position in VYNE Therapeutics in the fourth quarter valued at about $739,000. ADAR1 Capital Management LLC boosted its position in shares of VYNE Therapeutics by 319.2% in the first quarter. ADAR1 Capital Management LLC now owns 1,063,899 shares of the company’s stock worth $636,000 after buying an additional 810,108 shares during the period. Nantahala Capital Management LLC purchased a new stake in shares of VYNE Therapeutics in the fourth quarter worth about $580,000. T3 Companies LLC purchased a new stake in shares of VYNE Therapeutics in the fourth quarter worth about $548,000. Finally, Adage Capital Partners GP L.L.C. grew its stake in shares of VYNE Therapeutics by 87.2% in the second quarter. Adage Capital Partners GP L.L.C. now owns 644,134 shares of the company’s stock valued at $1,063,000 after buying an additional 300,000 shares in the last quarter. 83.78% of the stock is currently owned by institutional investors and hedge funds.

About VYNE Therapeutics

VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for vascular, inflammatory and fibrotic diseases. The company is advancing a pipeline of selective oral inhibitors that modulate key pathways implicated in chronic tissue damage and immune dysregulation. Headquartered in the San Francisco Bay Area, VYNE Therapeutics seeks to address high-unmet-need conditions by leveraging proprietary chemical and biological insights to create differentiated drug candidates.

The company’s lead program, VTX-002, targets the colony-stimulating factor-1 receptor (CSF-1R) pathway, which plays a central role in macrophage proliferation and activation.